Background and Aim. Despite tangible progress in recent years, substantial therapeutic challenges remain unexplored in nephropathy, particularly in diabetic patient. Addressing these challenges requires identification of novel drugs and development of noninvasive and cost-effective methods to select the most appropriate therapeutic option for the disease. Angiopathic nephropathy is one of the complications of diabetes mellitus and is becoming the single most important reason for end-stage renal disease in the western world. This study has investigated the inhibitory effect of a library naturally occurring nonprotein compounds that inhibit angiotensin converting enzyme (ACE). Materials and Methods. Docking studies of ACE protein with natural compounds and synthetic commercial drug perindopril were done using AutoDock, FlexX, and Hex. Toxicity predictions were carried out using OpenTox. Quantum mechanical properties were studied using GAMESS. Results. Pelargonidin-3-glucoside could be used as a potent renoprotective drug candidate, which inhibits ACEII. It has low toxicity and its quantum mechanical properties are comparable to those of commercial drugs. 1. Introduction Angiotensin converting enzyme (ACE) is an active participant in the body’s renin-angiotensin-aldosterone system for mediation of extracellular volume and arterial vasoconstriction. Secretion of this enzyme is carried by pulmonary and renal endothelial cells to catalyze the conversion of decapeptide angiotensin I to octapeptide angiotensin [1]. Apart from the normal catalysis activity, ACE also degrades bradykinin thus acting as a vasoconstrictor [2]. These two actions make ACE inhibition a potent target in the treatment of conditions such as hypertension, heart failure, and diabetic nephropathy. Inhibition of ACE results in the dwindled formation of angiotensin II and reduced catabolism of bradykinin, leading to systematic dilation of the arteries and veins and a decrease in arterial blood pressure. Inhibition of this enzyme also decreases the risk of end-stage renal disease (ESRD) in diabetics [3]. perindopril is a synthetic chemical drug which inhibits ACE; however, it causes dysfunctioning of the left ventricle of in Duchenne muscular dystrophy [4]. Considering the side effects of perindopril, the present study investigates the inhibitory effect of natural compounds in comparison with perindopril by insilico approach. 2. Materials and Methods To investigate the protein ligand interaction, the natural compounds and perindopril were docked into the active site of ACE predicted by pocket
References
[1]
M. Moser, C. Rosendorff, and W. B. White, “Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: is there a difference in response and any advantage to using them together in the treatment of hypertension?” Journal of Clinical Hypertension, vol. 10, no. 6, pp. 489–496, 2008.
[2]
M. E. Marketou and P. E. Vardas, “Bradykinin in the treatment of arterial hypertension: friend or foe?” Hellenic Journal of Cardiology, vol. 53, pp. 91–94, 2012.
[3]
S. Suissa, T. Hutchinson, J. M. Brophy, and A. Kezouh, “ACE-inhibitor use and the long-term risk of renal failure in diabetes,” Kidney International, vol. 69, no. 5, pp. 913–919, 2006.
[4]
D. Duboc, C. Meune, G. Lerebours, J. Y. Devaux, G. Vaksmann, and H. M. Bécane, “Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy,” Journal of the American College of Cardiology, vol. 45, no. 6, pp. 855–857, 2005.
[5]
“Marvin was used for drawing, displaying and characterizing chemical structures, substructures and reactions, Marvin 5.8.0 (324),” 2008, ChemAxon, http://www.chemaxon.com/.
[6]
O. Trott and A. J. Olson, “Software news and update AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading,” Journal of Computational Chemistry, vol. 31, no. 2, pp. 455–461, 2010.
[7]
M. Rarey, B. Kramer, T. Lengauer, and G. Klebe, “A fast flexible docking method using an incremental construction algorithm,” Journal of Molecular Biology, vol. 261, no. 3, pp. 470–489, 1996.
[8]
D. W. Ritchie and V. Venkatraman, “Ultra-fast FFT protein docking on graphics processors,” Bioinformatics, vol. 26, no. 19, Article ID btq444, pp. 2398–2405, 2010.
[9]
B. Bhattacharjee, T. Usha, S. Sadegh et al., “Computer aided screening of inhibitors to 5-α reductase type 2 for prostate,” Bioinformation, vol. 6, no. 7, pp. 262–265, 2011.
[10]
B. Bhattacharjee, R. M. Jayadeepa, R. Anantharamanan, S. S. Pillay, N. Kumari, and S. K. Middha, “Screening of novel inhibitors for MEK1 induced Breast Cancer-An Insilico Approach,” EMBnet Journal A, vol. 16, pp. 25–26, 2009.
[11]
E. F. Pettersen, T. D. Goddard, C. C. Huang et al., “UCSF Chimera-a visualization system for exploratory research and analysis,” Journal of Computational Chemistry, vol. 25, no. 13, pp. 1605–1612, 2004.
[12]
D. B. Turner, A. Rostami-Hodjegan, G. T. Tucker, and K. R. Yeo, “Prediction of non-specific hepatic microsomal binding from radily available physicochemical properties,” Drug Metabolism Reviews, vol. 38, no. 1, p. 162, 2006.
[13]
E. L. Willighagen, N. Jeliazkova, B. Hardy, R. C. Grafstr？m, and O. Spjuth, “Computational toxicology using the OpenTox application programming interface and Bioclipse,” BMC Research Notes, vol. 4, p. 487, 2011.
[14]
M. W. Schmidt, K. K. Baldridge, J. A. Boatz, et al., “General atomic and molecular electronic structure system,” Journal of Computational Chemistry, vol. 14, no. 11, pp. 1347–1363, 1993.
[15]
http://www.chemissian.com/.
[16]
Y. S. Moreno, G. S. Sánchez, D. R. Hernández, et al., “Characterization of anthocyanin extracts from maize kernels,” Journal of Chromatography Science, vol. 43, no. 9, pp. 483–487, 2005.
[17]
C. Felgines, O. Texier, C. Besson, B. Lyan, J. L. Lamaison, and A. Scalbert, “Strawberry pelargonidin glycosides are excreted in urine as intact glycosides and glucuronidated pelargonidin derivatives in rats,” British Journal of Nutrition, vol. 98, no. 6, pp. 1126–1131, 2007.
[18]
Y. Noda, T. Kaneyuki, A. Mori, and L. Packer, “Antioxidant activities of pomegranate fruit extract and its anthocyanidins: delphinidin, cyanidin, and pelargonidin,” Journal of Agricultural and Food Chemistry, vol. 50, no. 1, pp. 166–171, 2002.
[19]
S. K. Middha and T. Usha, “An in vitro new vista to identify hypoglycemic activity,” International Journal of Fundamental and Applied Science, vol. 1, no. 2, pp. 27–29, 2012.
[20]
T. Tanaka, G. I. Nonaka, and I. Nishioka, “Tannins and related compounds. C. Reaction of dehydrohexahydroxydiphenic acid esters with bases, and its application to the structure determination of pomegranate tannins, granatins A and B,” Chemical and Pharmaceutical Bulletin, vol. 38, no. 9, pp. 2424–2428, 1990.
[21]
L. Zhang, Q. Fu, and Y. Zhang, “Composition of anthocyanins in pomegranate flowers and their antioxidant activity,” Food Chemistry, vol. 127, no. 4, pp. 1444–1449, 2011.
